Benefits
Cognitive Function and Memory
Ginkgo biloba is often promoted for enhancing memory and cognitive performance, particularly in older adults. Some studies suggest it may improve attention, memory, and processing speed in healthy individuals or those with mild cognitive impairment. For example, it’s thought to enhance cerebral blood flow, which may support brain function. Evidence for Alzheimer’s disease or dementia is mixed. Some trials show modest benefits in slowing cognitive decline, while others find no significant effect compared to placebo.
Circulation and Cardiovascular Health
Ginkgo may improve blood circulation by dilating blood vessels and reducing blood viscosity. This can potentially help with conditions like peripheral artery disease or intermittent claudication (leg pain due to poor blood flow), where studies have shown improved walking distance. It’s also used to alleviate symptoms of poor circulation, such as cold hands and feet.
Antioxidant Properties
Ginkgo contains flavonoids and terpenoids, which act as antioxidants, neutralizing free radicals and reducing oxidative stress. This may help protect cells from damage linked to aging, heart disease, and neurodegenerative conditions.
Anxiety and Mood
Some evidence suggests ginkgo may reduce symptoms of anxiety, particularly in older adults or those with generalized anxiety disorder. Its effects are likely tied to improved cerebral blood flow and antioxidant activity.
Tinnitus and Hearing
Ginkgo is sometimes used to treat tinnitus (ringing in the ears), with mixed results. Some studies report reduced severity, while others show no benefit. It may be more effective in cases linked to poor blood flow.
Eye Health
Ginkgo may benefit conditions like glaucoma or age-related macular degeneration by improving blood flow to the eyes and protecting retinal cells from oxidative damage. Limited studies show potential for preserving vision in these conditions.
Mechanism of action
Antioxidant Activity
Mechanism: Flavonoids in ginkgo act as free radical scavengers, neutralizing reactive oxygen species (ROS) and reducing oxidative stress. This protects cells, particularly neurons and vascular tissues, from damage linked to aging, neurodegenerative diseases, and cardiovascular issues. May mitigate cellular damage in conditions like dementia, heart disease, and retinal degeneration.
Improved Blood Flow and Vasodilation
Mechanism: Ginkgo enhances microcirculation by promoting vasodilation (via nitric oxide pathways) and reducing blood viscosity. Ginkgolides inhibit platelet-activating factor (PAF), which reduces platelet aggregation and prevents excessive blood clotting. Supports cerebral and peripheral blood flow, potentially aiding cognitive function, reducing symptoms of intermittent claudication, and improving eye health in conditions like glaucoma.
Neuroprotection
Mechanism: Ginkgo protects neurons by reducing oxidative damage, stabilizing mitochondrial function, and modulating neurotransmitter activity (e.g., enhancing cholinergic signaling). Bilobalide may inhibit excitotoxicity by regulating glutamate release. May slow cognitive decline in mild cognitive impairment or Alzheimer’s and support brain health under stress (e.g., hypoxia).
Anti-Inflammatory Effects
Mechanism: Ginkgolides, particularly ginkgolide B, inhibit PAF, a mediator of inflammation, reducing inflammatory responses in tissues. Flavonoids also suppress pro-inflammatory cytokines. May alleviate symptoms in conditions involving inflammation, such as tinnitus or cardiovascular diseases.
Modulation of Neurotransmitters
Mechanism: Ginkgo may influence serotonin, dopamine, and acetylcholine systems, potentially enhancing mood and cognitive processing. It may also inhibit monoamine oxidase (MAO), increasing neurotransmitter availability. Could contribute to reduced anxiety and improved cognitive performance, though evidence is preliminary.
Mitochondrial and Cellular Protection
Mechanism: Ginkgo stabilizes mitochondrial membranes and enhances energy production, protecting cells from apoptosis (programmed cell death) under stress. Supports neuronal and vascular health, potentially benefiting conditions like dementia and ischemia.
Clinical trials
GEM (Ginkgo Evaluation of Memory) Study: randomized, double-blind, placebo-controlled trial (NCT00010803) in 3,069 community-dwelling adults aged 75+ with normal cognition or mild cognitive impairment receiving Ginkgo biloba extract EGb 761 (240 mg/day) vs placebo. Median follow-up ~6 years. (DeKosky et al. 2008, JAMA)
3,069 older adults aged 75+. 6-year follow-up.
PRIMARY ENDPOINT NEGATIVE: Ginkgo biloba did NOT significantly reduce overall incidence of dementia or Alzheimer's disease vs placebo. This was a major definitive negative trial that substantially weakened the case for Ginkgo as a dementia prevention agent.
Randomized, double-blind, placebo-controlled trial (NCT00276510) in 2,854 adults aged 70+ with self-reported memory complaints receiving EGb 761 (240 mg/day) vs placebo for 5 years. (Vellas et al. 2012, Lancet Neurol)
2,854 older adults with memory complaints. 5-year intervention.
PRIMARY ENDPOINT NEGATIVE: Ginkgo biloba did NOT significantly reduce conversion from memory complaints to Alzheimer's disease vs placebo. Combined with GEM Study, two large definitive trials with negative results in dementia/AD prevention. Modern view: Ginkgo is NOT supported by current evidence for primary prevention of dementia.
Randomized controlled trial in 90 patients (mean age 67) with vascular cognitive impairment (VCI) receiving Ginkgo biloba EGb 761 vs placebo over 24 weeks. Outcomes: cognitive scales (MMSE, NPI), QOL.
90 VCI patients. 24-week intervention.
Modest improvements in cognitive scores and quality of life vs placebo in VCI subgroup. Note: smaller positive trial in VCI specifically. Consistent with broader literature suggesting Ginkgo may have role in symptomatic management of established VCI/MCI even though it doesn't prevent dementia onset.
Phase IV, single-center, randomized, open-label trial in 100 MCI patients comparing EGb 761 (240 mg/day) vs donepezil (cholinesterase inhibitor) over 12 weeks. Outcomes: cognitive function, tolerability.
100 MCI patients.
Comparable cognitive improvements between EGb 761 and donepezil. CRITICAL CAVEAT: open-label design (not blinded), short duration, single center — limited rigor. Cannot conclude equivalence to pharmaceutical-grade dementia treatment. Better-tolerated than donepezil (less GI side effects, less bradycardia).
Placebo-controlled, double-blind, randomized trial in 309 patients with mild to moderate Alzheimer's disease or multi-infarct dementia receiving EGb 761 (120 mg/day) vs placebo for 52 weeks. (Le Bars et al. 1997, JAMA)
309 mild-moderate dementia patients. 52-week intervention.
Modest cognitive benefits on ADAS-Cog and clinical dementia rating scales vs placebo at 52 weeks. CRITICAL CONTEXT: this was an influential early trial that drove enthusiasm for Ginkgo in AD. Subsequent larger trials (GEM, GuidAge) failed to support primary prevention. Ginkgo has SOME role in symptomatic management of established mild-moderate dementia per the totality of evidence (Cochrane 2009 found weak positive signal), but should not be confused with disease modification.